RxDoctor Payments Data

Eleanara Iadgarova

Gerontology · Rego Park, NYNPI 1427430248

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Boehringer Ingelheim accounts for 69.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $315 and has fallen 71.0% since, to $91 in 2024.

$531in general payments, 2019–2025

Across 10 payments — averaging $53.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$369
  • Smith+Nephew$40
  • Pfizer$27
  • Grifols USA, LLC$23
  • Esperion Therapeutics, Inc.$23
  • AbbVie$19
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$531100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$531 in reported general payments places this provider in the 65th percentile of 187 gerontology providers in New York.

See all gerontology providers in New York

Medicare billing

Part B allowed, 2024
$146,900
Medicare patients
274
Services billed
1,355

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Diclofenac Sodium58$21,053
EliquisApixaban24$16,130
Silver Sulfadiazine69$959
Ammonium Lactate55$808
SsdSilver Sulfadiazine28$506
Cephalexin14$365
ClopidogrelClopidogrel Bisulfate35$222
Triamcinolone Acetonide16$105

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$27$16,13024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 187 gerontology providers in New York.

Other gerontology in Rego Park

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →